Literature DB >> 15172994

A novel role for mixed-lineage kinase-like mitogen-activated protein triple kinase alpha in neoplastic cell transformation and tumor development.

Yong-Yeon Cho1, Ann M Bode, Hideya Mizuno, Bu Young Choi, Hong Seok Choi, Zigang Dong.   

Abstract

Previously, no member of the mixed-lineage kinase (MLK) protein family was known to function as an oncogene. Here, we demonstrate that MLK-like mitogen-activated protein triple kinase (MLTK)-alpha, a member of the MLK family, induced neoplastic cell transformation and tumorigenesis in athymic nude mice. Introduction of small interference RNA (siRNA)-MLTK-alpha into MLTK-alpha-overexpressing cells dramatically suppressed cell transformation. Nuclear accumulation of the pHisG-MLTK-alpha fusion protein was observed after epidermal growth factor or 12-O-tetradecanoylphorbol-13-acetate treatment. Phosphorylation of downstream mitogen-activated protein kinase-targeted transcription factors including c-Myc, Elk-1, c-Jun, and activating transcription factor (ATF) 2 was also differentially enhanced in MLTK-alpha-overexpressing cells exposed to epidermal growth factor or 12-O-tetradecanoylphorbol-13-acetate stimulation compared with cells expressing mock vector or siRNA-MLTK-alpha. Very importantly, MLTK-alpha-overexpressing cells formed fibrosarcomas when injected s.c. into athymic nude mice, whereas almost no tumor formation was observed in mice that received injections of mock or siRNA-MLTK-alpha stably transfected cells. These results are the first to indicate that MLTK-alpha plays a key role in neoplastic cell transformation and cancer development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172994     DOI: 10.1158/0008-5472.CAN-04-0201

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Effect of vector-expressed shRNAs on hTERT expression.

Authors:  Ying Guo; Jun Liu; Ying-Hui Li; Tian-Bao Song; Jing Wu; Cai-Xia Zheng; Cai-Fang Xue
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

2.  RSK2 mediates muscle cell differentiation through regulation of NFAT3.

Authors:  Yong-Yeon Cho; Ke Yao; Ann M Bode; H Robert Bergen; Benjamin J Madden; Sang-Muk Oh; Svetlana Ermakova; Bong Seok Kang; Hong Seok Choi; Jung-Hyun Shim; Zigang Dong
Journal:  J Biol Chem       Date:  2007-01-09       Impact factor: 5.157

3.  Inhibition of mixed-lineage kinase (MLK) activity during G2-phase disrupts microtubule formation and mitotic progression in HeLa cells.

Authors:  Hyukjin Cha; Surabhi Dangi; Carolyn E Machamer; Paul Shapiro
Journal:  Cell Signal       Date:  2005-05-31       Impact factor: 4.315

4.  Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.

Authors:  Li Tan; Deepak Gurbani; Ellen L Weisberg; Douglas S Jones; Suman Rao; William D Singer; Faviola M Bernard; Samar Mowafy; Annie Jenney; Guangyan Du; Atsushi Nonami; James D Griffin; Douglas A Lauffenburger; Kenneth D Westover; Peter K Sorger; Nathanael S Gray
Journal:  Bioorg Med Chem       Date:  2016-12-07       Impact factor: 3.641

Review 5.  Chromatin-modifying enzymes as therapeutic targets--Part 2.

Authors:  Brian R Keppler; Trevor K Archer
Journal:  Expert Opin Ther Targets       Date:  2008-11       Impact factor: 6.902

6.  Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation.

Authors:  Yong-Yeon Cho; Ke Yao; Hong-Gyum Kim; Bong Seok Kang; Duo Zheng; Ann M Bode; Zigang Dong
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

7.  A regulatory mechanism for RSK2 NH(2)-terminal kinase activity.

Authors:  Yong-Yeon Cho; Ke Yao; Angelo Pugliese; Margarita L Malakhova; Ann M Bode; Zigang Dong
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

8.  Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer.

Authors:  Yun Feng; Yanru Wang; Hongliang Liu; Zhensheng Liu; Coleman Mills; Kouros Owzar; Jichun Xie; Younghun Han; David C Qian; Rayjean J Hung Rj; Yonathan Brhane; John McLaughlin; Paul Brennan; Heike Bickeböller; Albert Rosenberger; Richard S Houlston; Neil Caporaso; Maria Teresa Landi; Irene Brüske; Angela Risch; Yuanqing Ye; Xifeng Wu; David C Christiani; Christopher I Amos; Qingyi Wei
Journal:  Mol Carcinog       Date:  2017-10-31       Impact factor: 4.784

9.  The MAP3K ZAK, a novel modulator of ERK-dependent migration, is upregulated in colorectal cancer.

Authors:  C Rey; B Faustin; I Mahouche; R Ruggieri; C Brulard; F Ichas; I Soubeyran; L Lartigue; F De Giorgi
Journal:  Oncogene       Date:  2015-11-02       Impact factor: 9.867

10.  Prediction of molecular targets of cancer preventing flavonoid compounds using computational methods.

Authors:  Hanyong Chen; Ke Yao; Janos Nadas; Ann M Bode; Margarita Malakhova; Naomi Oi; Haitao Li; Ronald A Lubet; Zigang Dong
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.